Problem

Clinical research coordinators often spend hours manually transcribing values from source documents into electronic data-capture (EDC) case-report forms. The work is repetitive and poorly matched to trained clinical staff: each typed character creates a risk of a wrong digit, unit, or date, and small errors can later generate queries that require additional research, correction, and verification. Gleam’s stated economics are concrete: its users report saving 20 minutes of paid employee time per visit, while research sites using the product report reclaiming more than half of their data-entry time and, for heavy screening visits, several hours.

The killer use case is the post-visit handoff from source data to the EDC. After a coordinator completes a visit, they use Gleam in the browser to move the relevant information into the study’s CRFs, review it, and submit it, rather than conducting a field-by-field transcription marathon. The intended result is to return coordinators to patient care while reducing data-quality problems and downstream queries.

Product / Service

Gleam is a browser-based data-entry assistant for research sites, delivered as a lightweight browser extension that works alongside existing eSource systems and EDCs. It learns what the EDC fields expect, fetches visit data from browser-based source systems, fills the CRFs, flags uncertain fields for coordinator review, and maintains links between each entered value and its source so users can perform quality control. The company says sites can start without custom integrations, a server deployment, or sponsor approval, and that the coordinator remains accountable for reviewing and signing the data.

The benefit is faster, more accurate, and more auditable data entry without asking a site to replace its existing EDC. Gleam’s product materials emphasize source and destination traceability, while its customer evidence points to reclaimed staff time and improved data quality. Current product information supports browser-based eSource; paper and PDF source support is described as forthcoming in the product tour, although the company’s later 2026 positioning discusses support for those formats.

Market

Gleam competes in clinical-trial site operations and eClinical workflow automation, specifically source-to-EDC data-entry assistance. Its closest practical alternative is still manual transcription. Adjacent alternatives include EDC platforms such as Medidata Rave and OpenClinica, but Gleam explicitly positions itself as neither an EDC nor an EDC replacement: it is designed to work alongside whatever EDC a study already uses. The reviewed public material describes other vendors as having attempted to address manual data entry, but does not identify a specific like-for-like direct competitor by name.

The company appears to be an early commercial startup rather than a mature scaled vendor. Y Combinator lists Gleam as founded in 2023, a Summer 2023 company, and active, while the company site cites coordinators and site leaders using the product and invites prospects to request a demo. Public evidence demonstrates customer usage and reported time savings, including a named site director’s testimonial, but does not disclose revenue, paid-customer counts, or enough information to conclude that Gleam is either definitively pre-revenue or at meaningful scale.